Brands, Medical Use, Clinical Data
Drug Category
- Antiparkinson Agents
- Antidyskinetics
Dosage Forms
Brands / Synonyms
Alti-Bromocriptine; Apo-Bromocriptine; Bromergocryptine; Bromocriptin; Bromocriptina [Inn-Spanish]; Bromocriptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptine [Usan:Ban:Inn]; Bromocriptinum [Inn-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine; Parlodel; Parlodel Snaptabs
Indications
For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly.
Pharmacology
Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.
Mechanism of Action
Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Not Available
Contraindications
Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia
bromocriptine mesylate should be withdrawn when pregnancy is diagnosed. In the event that bromocriptine mesylate is
reinstituted to control a rapidly expanding macroadenoma and a patient experiences a hypertensive disorder of
pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use
during a hypertensive disorder of pregnancy. When bromocriptine mesylate is being used to treat acromegaly,
prolactinoma, or Parkinsonís disease in patients who subsequently become pregnant, a decision should be made
as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug
should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia,
preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be
medically contraindicated. The drug should not be used during the post-partum period in women with a history of
coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically
contraindicated. If the drug is used in the post-partum period the patient should be observed with caution.
Drug Interactions
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated,
but alcohol may potentiate the side effects of bromocriptine mesylate. Bromocriptine mesylate may interact with
dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased
efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of
bromocriptine mesylate with other ergot alkaloids is not recommended.
|
